Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens

Chappe C, Padovani L, Scavarda D et al (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23:574–583

Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405

Myung JK, Cho H, Park CK et al (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5:430–436

Lee D, Cho YH, Kang SY et al (2015) BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. J Surg Oncol 111:359–364

Ho CY, Mobley BC, Gordish-Dressman H et al (2015) A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol 130:575–585

Collins VP, Jones DT, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:775–788

Rodriguez FJ, Lim KS, Bowers D et al (2013) Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol 8:361–379

Burger PC, Scheithauer BW (2007) Tumors of the central nervous system. American Registry of Pathology, Washington

Becker AJWO, Figarella-Branger D, Blumcke I, Capper D (2016) WHO classification of tumours of the central nervous system. International Agency of Research on Cancer, Lyon

Preusser M, Laggner U, Haberler C et al (2006) Comparative analysis of NeuN immunoreactivity in primary brain tumours: conclusions for rational use in diagnostic histopathology. Histopathology 48:438–444

Dasgupta T, Olow AK, Yang X et al (2016) Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol 126:385–393

Capper D, Preusser M, Habel A et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19